Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: The REPLACE-MS studyKiranpal Singh Sangha, Ahmed Z Obeidat, Michelle Maynard et al.|Multiple Sclerosis Journal|2026Cited by 1